NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 9 July 2025

**Location:** Hybrid via Manchester offices and Zoom

## Attendees

Committee members present

1. Dr Megan John (Chair) Present for all items
2. Dr Raju Reddy (Vice Chair) Present for all items
3. Andrew Fox Present for all items
4. Dr Ben Searle Present for items 1 to 6.2
5. Dr Bernard Khoo Present for all items
6. Carole Pitkeathley Present for all items
7. Catherine Thompson Present for all items
8. Professor David Meads Present for all items
9. Giles Monnickendam Present for all items
10. Martin Bradley Present for all items
11. Dr Matthew Bradley Present for items 6 to 6.2.2
12. Dr Miranda Trevor Present for items 1 to 6.2
13. Dr Nathan Moore Present for items 1 to 5.2.2
14. Dr Robert Hodgson Present for items 1 to 5.2.2
15. Dr Salman Waqar Present for all items
16. Samuel Finnikin Present for all items
17. Dr Savvas Vlachos Present for all items
18. Professor Sofia Dias Present for all items
19. Sophia Steer Present for all items
20. Sue Wen Leo Present for all items
21. Dr Will Sullivan Present for all items
22. Dr Zenas Yiu Present for items 1 to 6.2

NICE staff (key players) present

Lorna Dunning, Associate Director Items 1 to 4.2.2, 6 to 6.2.2

Louise Jafferally, Project Manager Items 1 to 4.2.2

Rachel Williams, Heath Technology Assessment Adviser Items 1 to 4.2.2

Lauren Elston, Heath Technology Assessment Analyst Items 1 to 4.2.2

Lizzie Bell, Associate Director Items 5 to 5.2.2

Kate Moore, Project Manager Items 5 to 6.2.2

Mary Hughes, Heath Technology Assessment Adviser Items 5 to 5.2.2

Madiha Adam, Heath Technology Assessment Analyst Items 5 to 5.2.2

Alex Sampson, Heath Technology Assessment Adviser Items 6 to 6.2.2

Tom Palmer, Heath Technology Assessment Analyst Items 6 to 6.2.2

External assessment group representatives present

Stephen Rice, Newcastle NIHR TAR Team, Newcastle University Items 1 to 4.1.3

Julia Whitehall, Newcastle NIHR TAR Team, Newcastle University Items 1 to 4.1.3

Ed Wilson, Peninsula Technology Assessment Group, University of Exeter Items 5 to 5.1.3

Jemma Perks, Peninsula Technology Assessment Group, University of Exeter Items 5 to 5.1.3

Rob Hodgson, Centre for Reviews and Dissemination and Centre for Health Economics, University of York Items 6 to 6.1.3

Alexis Llewellyn, Centre for Reviews and Dissemination and Centre for Health Economics, University of York Items 6 to 6.1.3

Clinical, Patient & NHS England experts present

Shobhit Baijal, Consultant Medical Oncologist, clinical expert nominated by Accord Items 1 to 4.1.3, 6 to 6.1.3

James Richardson, National Specialty Advisor (Cancer Drugs), commissioning expert Items 1 to 4.1.3, 6 to 6.1.3

Dr Palak Trivedi, Consultant Hepatologist, clinical expert nominated by Gilead Items 5 to 5.1.3

Robert Mitchell Thain, CEO of PBC Foundation, patient expert nominated by PBC Foundation Items 5 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Vice Chair, Dr Raju Reddy, welcomed members of the committee and other attendees present to the meeting.
	2. The Vice Chair noted apologies from Dr Guy Makin, Paul Caulfield, and Philip Mallender.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on 12 June 2025.

### Appraisal of Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]

* 1. Part 1 – Open session
		1. The Vice Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Accord Healthcare.
		2. The Vice Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11405).
		3. The Vice Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Will Sullivan, Dr Salman Waqar, and Carole Pitkeathley.
	2. Part 2 – Closed session (company representatives, professional experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the [topic webpage](https://www.nice.org.uk/guidance/indevelopment/gid-ta11405) in due course.

### Appraisal of Seladelpar for previously treated primary biliary cholangitis [ID6429]

* 1. Part 1 – Open session
		1. The Chair, Dr Megan John, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Gilead.
		2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11540).
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Ben Searle, Giles Monnickendam, and Carole Pitkeathley.
	2. Part 2 – Closed session (company representatives, professional experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the [topic webpage](https://www.nice.org.uk/guidance/indevelopment/gid-ta11540) in due course.

### Appraisal of Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]

* 1. Part 1 – Open session
		1. The Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Pfizer.
		2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11570).
		3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by the chair.
	2. Part 2 – Closed session (company representatives, professional experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the [topic webpage](https://www.nice.org.uk/guidance/indevelopment/gid-ta11570) in due course.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Wednesday 13 August 2025 and will start promptly at 9am.